XELIRI compared with FOLFIRI as a secondline treatment in patients with metastatic colorectal cancer

Author：                  

Publisher： Spandidos Publications

ISSN： 1792-1074

Source： Oncology Letters, Vol.8, Iss.4, 2014-01, pp. : 1864-1872

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer

By                    

Oncology Letters, Vol. 2, Iss. 3, 2011-01 ,pp. : 493-498

Spandidos Publications

Access to resources Recommend Favorite

Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)

By Hebbar Mohamed   Tournigand Christophe   Lledo Gérard   Mabro May   André Thierry   Louvet Christophe   Aparicio Thomas   Flesch Michel   Varette Charles   de Gramont Aimery   Group (GERCOR) Oncology  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 154-159

Informa Healthcare

Access to resources Recommend Favorite

Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU - a retrospective comparison of treatment regimens

By Iveson T.J.   Hickish T.   Schmitt C.   Van Cutsem E.  

European Journal of Cancer, Vol. 35, Iss. 13, 1999-12 ,pp. : 1796-1804

Elsevier

Access to resources Recommend Favorite

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study

By Kochi Mitsugu   Akiyama Yuji   Aoki Tatsuya   Hagiwara Ken   Takahashi Takao   Hironaka Katsuji   Teranishi Futoshi   Osuka Fumihiko   Takeuchi Masahiro   Fujii Masashi   Nakajima Toshifusa  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1097-1102

Springer Publishing Company

Access to resources Recommend Favorite

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite